English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 18 December 2020, 11:00 HKT/SGT

Source: ZENUM Sarl
Five-minute Covid test will reveal if vaccine still works
Identify from a drop of blood whether a person's Covid-19 vaccine is still valid, in 5 Minutes!

Epalinges, Switzerland, Dec 18, 2020 - (ACN Newswire) - Swiss high-tech company ZENUM has developed one of the most advanced technologies in the fight against Covid-19, and it could be ready for distribution as early as next month. The world's first five-minute portable Coronavirus test will also detect how much immunity remains after taking a vaccine.

NANOFLUIDIC RAPID TEST KIT - Identify from a drop of blood whether a person's Covid-19 vaccine is still valid - in 5 Minutes! ZENUM SWITZERLAND 2021

The game-changing ZEKNANO rapid test kit uses a tiny finger-prick blood sample, instead of swabs. It can be taken anywhere, has close to 100% accuracy, and also measures severity of infection. Thanks to nanotechnology, ZEKNANO not only detects Covid-19 within five minutes, but it identifies up to 14 different conditions simultaneously, including flu virus and infectious diseases.

Artificial Intelligence (AI) is at the heart of the revolutionary product. A neural network - a series of algorithms designed to function like a human brain - has been added to increase the test's efficiency, and study any mutation of the virus.

As the device is portable and lightweight, the tests do not have to be administered only in medical settings. This makes it a leading contender to tackle coronavirus and other diseases in the developing world. It also has the potential to help control the pandemic across all countries before another possible surge in the coming months.

ZENUM already produces 15-minute coronavirus rapid test kits for antibodies and antigens, under the brand ZEKMED. The performance evaluation of these kits were conducted by CIRION Biopharma, one of the few CLIA laboratories in Canada. The results are in accordance with three independent evaluations conducted in Russia, Switzerland and France.

The new ZEKNANO five-minute test is expected to be certified for use in January, putting it ahead of several ongoing projects to achieve such rapid results.

Emidio Do Sacramento, founder and CEO of ZENUM, said: "It doesn't matter if it's a 5 or 15 minute rapid test. Our focus is to help practitioners and health institutions, the best we can, to save lives.

"The reality is that the world is in need of products that solve a problem, and not a marketing sales campaign promoting companies or universities, whether that product is from our company or any other.

"Enough is enough. Mass testing, fast and accurate patient triage is the only reliable solution before any vaccine reaches enough people. We need our lives and economy back to 'normal'."

ZENUM's origins are rooted in a collaborative network of innovators who strive in the development of applications/mediums/security using biometrics, Ai and blockchain technologies and the infinite influences these technologies will have on life.

As a result of our developments in these fields with our project collaborators and likeminded partners, we found ourselves already engaged and working in the field of medical pre-diagnosis using biometric data for example the research into the pre-diagnosis of glaucoma.

ZENUM is located in new facilities at BIOPOLE, the Life Sciences Campus - one of the largest healthcare research campuses in Europe, and has important medical partnerships in Switzerland, Germany and China. Full technical details can be found at https://zekmed.com/zeknano.html

For more information, please contact:
Emidio Do Sacramento, CEO, Zenum
E: es@zenum.swiss, es@zekmed.com, https://zekmed.com

About the CEO:

Topic: Press release summary
Source: ZENUM Sarl

Sectors: Healthcare & Pharm, MedTech
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation  
May 17, 2024 22:29 HKT/SGT
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit  
May 17, 2024 20:09 HKT/SGT
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market  
May 17, 2024 18:00 HKT/SGT
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards  
May 17, 2024 16:37 HKT/SGT
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London  
May 17, 2024 15:48 HKT/SGT
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers  
May 17, 2024 15:00 HKT/SGT
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers  
May 17, 2024 15:00 HKT/SGT
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning  
Friday, May 17, 2024 1:03:00 PM
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud  
Friday, May 17, 2024 10:19:00 AM
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim  
May 16, 2024 22:00 HKT/SGT
More Press release >>
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575